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Summary
Background: There is still no reliable, specific biomarker
for precision diagnosis and clinical monitoring of systemic
lupus erythematosus. The aim of this study was to investi-
gate the importance of the determination of immunofeno-
typic profiles (T, B lymphocytes and NK cells) and serum
cytokine concentrations (IL-17 and IFN-alpha) as potential
biomarkers for this disease.
Methods: The study included 55 patients with SLE and 25
healthy controls. The proportion of T, B, NK cells were
assessed in peripheral blood using flow cytometric assays
while the serum cytokine concentration (IL-17 and IFN-
alpha) was determined by ELISA test.
Results: ROC curve analysis showed good accuracy to
distinguish between patients and healthy individuals for
activated T cells (AUC=0.798; p<0.001), Treg (AUC=
0.651; p=0.036), and memory B cells (AUC=0.285;
p=0.002). We found statistically significant difference
(p=0.036) in the levels of serum IL-17 between patients
with SLE (IL-17=49.27 pg/mL) and controls (IL-17=
28.64 pg/mL).
Kratak sadr`aj
Uvod: Jo{ uvijek ne postoji pouzdan, specifi~an biomarker
za precizno dijagnosticiranje i klini~ko pra}enje sistemskog
lupus eritematodesa. Cilj ovog istra`ivanja je da se ispita
zna~aj odre|ivanja imunofenotipskog profila (udio T, B lim-
focita i NK }elija) i serumske koncentracije citokina (IL-17
i IFN-alfa) kao potencialnih biiomarkera za ovo oboljenje. 
Metode: U studiju je uklju~eno 55 pacijenata oboljelih od
SLE i 25 zdravih osoba. Za odre|ivanje imunofenotipskog
profila (T, B limfociti i NK }elije), iz periferne krvi ispitanika,
kori{tena je metoda proto~ne citometrije, dok je koncentra-
cija citokina u serumu (IL-17 i IFN-alfa) odre|ena ELISA
metodom.
Rezultati: Analizom ROC krive uo~ena je statisti~ki zna~ajna
razlika za udio aktiviranih T limfocita (AUC=0,798; p<
0,001), T regulatornih limfocita (AUC=0,651; p=0,036),
i memorijskih B }elija (AUC=0,285; p=0,002) izme|u
pacijenata sa SLE i zdravih individua. Prona{li smo zna -
~ajno ve}i nivo serumskog IL-17 (p=0,036) kod pacijenata
sa SLE (IL-17=49,27 pg/mL) u odnosu na kontrolnu
grupu (IL-17=28,64 pg/mL).
List of abbreviations: ACR, American College of Rheumatology;  APC,
allophycocyanin; AUC, Area under the curve; Breg, B regulatory cells;
CI, Confidence Interval; ENA, extractable nuclear antigens;  FITC, flu-
orescein isothiocyanate; IFN, interferon; IL, interleukin; NPV, negative
predictive value; PE, phycoeryrhrin; PerCP, peridinin-chlorophyll protein
complex; p, probability; PPV, positive predictive value; ROC, Receiver
operating characteristic; SEN, sensitivity, SLEDAI, Systemic Lupus
Erythe matosus Disease Activity Index; SLICC, Systemic Lupus
International Collaborating Clinics; SPE, specificity; TCR, T-cell recep-
tor; Treg, T regulatory cells.
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Introduction
Systemic lupus erythematosus (SLE) is clinically
and serologically diverse autoimmune disease of
unknown aetiology. It is characterized by the presence
of autoantibodies, primarily to the nuclear material of
the cell, and by the deposition of immune complexes
in various tissues (1, 2). The specific class of autoan-
tibodies are anti-nuclear antibodies (ANA). These
antibodies are capable of binding and destroying cer-
tain structures within the nucleus of cells. There are
two main groups of ANA: autoantibodies to DNA
(single and double stranded) and autoantibodies to
extractable nuclear antigens (ENA): SSA/Ro, SSB/La,
Sm, Sm/RNP, Scl-70, Jo-1 (3).
Patients with SLE typically suffer exacerbations
of the disease, with periods of remission between
these. It predominantly affects younger women, but
can occur in up to 20% of patients aged 50 years or
older. The disease affects almost every system in the
body, with varying degrees of severity. It can occasion-
ally be refractory to therapy, and is associated with a
higher mortality rate than that of the general popula-
tion. In a certain proportion of patients SLE gradually
worsens over time, so the resulting organ damage
can be life threatening (4). Despite improvements in
survival of patients with SLE, the standardized mortal-
ity ratios (SMR) are still 3-fold higher than for the gen-
eral population. Infections, cardiovascular disease,
and end-organ damage remain the major causes of
death (5). SLE can affect several organs, and has an
unpredictable disease course (6, 7).
As in all autoimmune diseases, loss of tolerance,
in both T and B cells, plays a significant role in the
pathogenesis of SLE. Recent studies focusing on the
immuno-pathogenesis of the disease suggest that
some patients have a genetic predisposition towards
loss of tolerance to autoantigens (damaged immuno-
regulation of T cells), causing overproduction of auto -
antibodies responsible for the resultant tissue and
organ destruction (autoreactive B lymphocytes) (8, 9).
T cells of patient with SLE display numerous phenotyp-
ic and numerological abnormalities, thereby contribut-
ing to SLE pathogenesis and serving as a potentially
rich source of SLE biomarkers (10). Significant T cells
in SLE include: T-helper cell type 1 (Th1), T-helper cell
type 2 (Th2), Th17 cells, follicular T cells (Tfh) and T-
regulatory (Treg) cells. T cells from SLE patients are
more resistant to induction of apoptosis by thymic stro-
mal cells (11). The TCR complex on the surface of T
lymphocyte, consists of a T-cell receptor (TCR), CD3
and  (zeta) chain. According to their function, T cells
are separated into T helper cells (CD4+) and their
cytotoxic T lymphocytes (CD8+). The activation of T
lymphocytes is characterized by the expression of num-
ber of antigens, including HLA-DR (12). 
The diagnosis of SLE is based on criteria set by
the American College of Rheumatology (ACR), which
were developed in 1971, revised in 1982 and in
1997. These criteria were newly revised and validated
by Systemic Lupus International Collaborating Clinics
(SLICC) group in 2012. According to SLICC, a SLE
positive patient must satisfy at least 4 from 17 criteria,
including at least 1 of 11 clinical criteria and 1 of 6
laboratory criteria (13). The activity and severity of
disease are measured using several indexes such as
the SLEDAI – Systemic Lupus Erythematosus Disease
Activity Index (14). 
Improved understanding of the immunological
basis and pathological mechanisms of SLE has resulted
in tangible benefits to patients, such as the introduction
of targeted therapy. However, there remains a lack of
reliable biomarkers to recognize the disease, predict
response to therapy, and monitor this response (15).
The aim of this study was to examine the role of several
biomarkers (T and B lymphocytes, IL-17, IFN-a) as
potential biomarkers for the diagnosis of SLE, and as
markers of disease severity and progression.
Material and Methods
Fifty five (N=55) SLE patients were included in
the study (4 male and 51 female), with an average
age of 33 (25.5–40.0) years. 
Inclusion criteria: All SLE patients fulfilled the
revised ACR classification criteria: malar and discoid
Conclusions: Significant increase in the relative number of
Treg lymphocytes, and decrease in memory B cells, as well
as decrease level of IL-17, in SLE patients may be implicat-
ed in the pathogenesis of the disease. These parameters,
as biomarkers, could distinguish SLE patients and no-SLE
patients. Monitoring subpopulations of immune cells in
peripheral blood using flow cytometry provides insight into
abnormal T and B cell function in SLE. Progress in under-
standing the immunity at SLE, results in concrete benefits
for the SLE patients, which include new clinical manage-
ment and therapeutic strategies. 
Keywords: SLE, biomarkers, T and B lymphocytes, cyto -
kines, flow cytometry
Zaklju~ak: Zna~ajno pove}anje relativnog broja Treg limfo-
cita i smanjenje memorijskih B }elija, kao i pove}anje nivoa
IL-17 kod pacijenata s SLE mo`e biti povezano sa patoge-
nezom bolesti. Ovi parametri, kao biomarkeri, zbog njihove
odli~ne specifi~nosti, mogu razlikovati osobe sa i bez SLE-
a. Monitoring subpopulacija imunih }elija u perifernoj krvi
pomo}u proto~ne citometrije omogu}ava uvid u abnormal-
nu funkciju T i B limfocita u SLE. Napredak u razumijeva-
nju imunolo{ke osnove kod SLE-a rezultira konkretnom
koristi za pacijente sa ovim oboljenjem, {to podrazumjeva
nove na~ine klini~kog pra}enja pacijenta i nove terapijske
strategije.
Klju~ne re~i: SLE, biomarkeri, T i B limfociti, citokini,
proto~na citometrija
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rash, photosensitivity, oral ulcers, arthritis, serositis,
renal, neurological, hematologic and immunologic
disorder, and positive antinuclear antibody. The pres-
ence of 4 out of 11 criteria confirmed the diagnosis
of SLE (16).
Exclusion criteria: age less than 18 years;
patients with confirmed HIV infection or any other
immune deficient; patients undergoing biologic ther-
apy; patients with metastatic disease and acute infec-
tious disease.
SLE group: Most patients (N=45, 81.8%)
included in this study were under routine follow-up in
the Rheumatology Department at the Clinical Center
in Sarajevo from January 2014 to October 2015. Five
(9.1%) patients were being treated at the Department
of Nephrology, and 5 (9.1%) patients were hospital-
ized at the Department of Dermatology at Clinical
Center in Sarajevo during the same period. At every
inspection, patients were clinically evaluated for the
presence of signs and symptoms of SLE, and they
underwent biochemical laboratory tests and specific
immunology tests, and immunological profile (T, B,
NK, cytokines). The immunological research of this
study was carried out at the Department of Clinical
Immunology at Clinical Center of Sarajevo.
Control group: 25 healthy individuals were
matched for age and gender with the SLE group.
Subjects for the healthy control group were randomly
selected from the pool of representative blood sam-
ples of healthy adults. This group was not subjected
to additional diagnostic procedures. 
The blood samples for immune analysis were
taken into two tubes: (i) a tube with a gel for determi-
nation of IFN-a and IL-17 by ELISA (Enzyme-linked
immunosorbent assay), (ii) and the second with an
anticoagulant EDTA (ethylene-diamine tetra-acetate)
to determine the expression of T and B cells by flow
cytometry. Levels of IFN-a from the serum of SLE
patients was determined by standardized VeriKine
Human Interferon Alpha Multi-Subtype Serum ELISA
kit (PBL Assay Science, New York, USA), and for the
detection of IL-17 levels, a R&D SystemsTM Human
IL-17 kit (R&D SystemsTM, Inc. Minneapolis, USA)
was used.
Immunophenotyping of lymphocytes 
In order to evaluate the immune status, we anal-
ysed peripheral blood lymphocytes using flow cytom-
etry (diagnostic technique), which was performed on
BD FACS Canto II (Becton Dickinson, New York, USA)
instrument. After acquisition, data were analysed with
Diva Software, version 6.1.3 (DB Bioscience).
Immunophenotyping of cells was carried out with
standard method of sample preparation. Human lym-
phocytes, after lysis of erythrocytes, were stained with
monoclonal antibodies (Abs) conjugated to: FITC (flu-
orescein isothiocyanate), PE (phycoeryrhrin), PerCP
(peridinin-chlorophyll protein complex) and APC
(allophycocyanin). All Abs volumes were 20 mL, exept
for APC, which was 5 mL. Previously pipetted antibod-
ies were added to a 100 mL whole blood sample and
then incubated for 15–30 min. FACS Lysing Solution
(2 mL) was added to the sample and incubated for 10
min. The cells were washed with 2–3 mL CellWash,
twice, and then pelleted and resuspended for flow
cytometric analysis. Every time, between procedure
steps, the cells were incubated at room temperature
(25–30 °C) in the dark place. All Abs and solutions
were provided by BD Bioscience (San Jose, CA, USA)
and are summarized in Table I. Furthermore, Treg
(CD4+CD25++FoxP3+CD127-), Breg (CD19+
CD24+CD38+), memory B (CD19+CD24+38-),
mature (CD19+CD24+CD38inter) were also evalua-
ted. cyFox P3 was prepared according to principles of
intracellular staining.
Ethics
The Institutional Ethics Committee reviewed and
approved the study design. Patients were informed
and agreed with publishing of their data.
Statistical analysis
Statistical analysis was performed using SPSS
21.0 software for Windows (SPSS, Chicago, IL, USA).
The Shapiro-Wilk test was used to test normality and
variance homogeneity of data. Data were presented
as median and interquartile ranges for skewed vari-
ables. Categorical variables were shown as frequen-
cies and analysed using Pearson’s chi-square test.
The difference in normally distributed data was tested
with independent t-test. The differences in parame-
ters values showing skewed distribution were assessed
by Mann-Whitney U test. To determinate the accuracy
and respective best cut-off values of biomarkers dif-
Table I Combinations of cells surface markers for the fluo-
rescently labelled monoclonal antibodies.
FITC, Fluorescein Isothiocyanate; PE, Phycoerythrin; APC,
Allophycocyanin; PerCP, Peridin hlorophill protein complex; CD3,
T lymphocytes; CD4, T helper lym; CD8, T cytotoxic lym; CD19,
B cells; CD16+56, Natural killer cells; HLA-DR, marker for acti-
vated cells; CD45, leukocytes, FoxP3, forkhead box P3; CD25
and CD38, activation lymphocytes markers.
FITC PE PerCP APC
T1 T1 CD3 CD8 CD45 CD4
T2 T2 CD3 CD16+56 CD45 CD19
T3 T3 CD3 HLA-DR CD45 –
T4 T4 CD3 cyFoxP3 CD4 CD25
T5 T5 CD38 CD24 CD45 CD19
ferentiating SLE patients from healthy controls,
Receiver Operating Characteristic (ROC) curves were
designed. The accuracy of diagnosing measures was
calculated with 95% confidence interval (95% CI). A
p value <0.05 was considered statistically significant
for all comparisons. 
Results
Demographics
The study included a total of 80 subjects; 25
healthy controls and 55 SLE patients with disease at
various stages based on the SLEDAI score. All
patients were diagnosed according to the ACR criteria
(at least 4 out of 11 criteria). Active vs. non-active
stage of disease were discriminated according to ACR
classification criteria, clinical evaluation, SLEDAI
score >4 and compulsory positive antinuclear anti-
bodies for active SLE. There were no statistically sig-
nificant differences in age or in gender between the
patient and the control group (Table II). 
Immunophenotyping profile (CD3, CD4, CD8,
CD19, NK and Ratio)
Table III summarizes the immuno-phenotype
profile of T, B, NK cells. The relative values of activat-
ed T cells (CD3HLA-DR+), B lymphocytes (CD19+),
regulatory T cells (Treg), and values of serum IL-17
were significantly higher in the SLE group than in the
control group. Meanwhile average value of memory B
cells was statistically lower for SLE patients compared
to the control group. For other parameters, Student’s
t-test for independent samples did not demonstrate
any statistical significance when comparing the aver-
age values of analysed groups. Moreover, the per-
centage of Treg cells was significantly decreased in
patients with active compared to non-active stage of
disease (Table IV). IL-17 was much higher in active
SLE (54.84 pg/mL) compared to non-active (31.27
pg/mL), but the difference was not statisically signifi-
cant (p=0.106). Other parameteres did not show
significant difference between stages of SLE.
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Table II Baseline characteristics of SLE patients and patients
in the control group.
Table III Immunophenotype profile: relative values of T, B, NK cells in SLE patients vs. control group.
*Data are presented as median (25th and 75th percentiles);
NS-not significant compared between SLE and control group;
p-probability; *Fisher’s Exact Test; **Pearson Chi-Square Test
*95% CI Mean-95% confidence interval; n-sample size, t-independent t-test, SD-standard deviation, p-probability rejection of the null
hypothesis
Variables SLE group(n=55)
Control group
(n=25) p-value
Age (years) 33.0 (25.5–40) 33.0 (27–46) 0.614* (NS)
Sex       female
male
51 (92.7%) 23 (92.0%) 0.909** (NS)
4 (7.3%) 2 (8.0%)
SLEDAI  female
male
18.9 (5.0–32.0) /
6.9 (2.9–15) /
Groups
t pSLE group (n=55) Control group (n=25)
Mean±SD Mean±SD
CD3 (%) 76.76±9.31 76.28±6.91 0.23 0.819
CD4 (%) 45.09±11.74 46.35±6.87 -0.60 0.551
CD8 (%) 28.58±11.42 25.03±7.27 1.68 0.098
CD3HLA-DR (%) 15.51±8.35 8.01±3.83 <0.001
CD19 (%) 10.43±6.23 8.15±3.63 2.06 0.043
NK (%) 11.71±7.39 13.13±5.96 -0.85 0.401
Ratio 1.95±1.17 2.02±0.68 -0.92 0.363
Treg (%) 9.79±5.05 7.35±1.64 -2.309 0.024
Breg (%) 10.02±7.17 8.86±4.14 -0.750 0.456
Memory B (%) 25.11±19.30 33.71±11.73 2.048 0.044
Mature B (%) 55.13±18.96 51.96±11.16 -0.773 0.442
IL-17 (pg/mL) 49.27±45.88 28.64±21.70 -2.136 0.036
IFN-a (pg/mL) 0.47±1.63 0.24±0.44 -0.691 0.491
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Values of biomarkers for SLE prediction 
The ROC curve for accurate prediction of SLE
showed that proportion of activated T cells (CD3HLA-
DR+) in the SLE patients vs. healthy controls, propor-
tion of regulatory T lymphocytes and proportion of
memory B lymphocytes demonstrated a significant
area under the curve, shown in Figure 1. ROC curve
Table IV Immunophenotype profile: relative values of T, B,
NK cells in SLE patients with active vs. non-active disease.
Table V Optimal cut-off values, area under the curve with 95% confidence interval (AUC, 95% CI), sensitivity, specificity, positive
and negative predictive value for biomarkers in differentiating between SLE group and healthy controls.
SLE
pActive 
(n=14)
Non-active
(n=41)
CD3 (%) 76.42±9.04 76.88±9.50 0.526
CD4 (%) 43.52±14.00 45.63±11.00 0.217
CD8 (%) 29.61±13.42 28.23±10.81 0.700
CD19 (%) 11.09±6.12 10.20±6.32 0.280
NK (%) 11.61±8.06 11.74±7.25 0.977
Ratio 1.85±1.03 2.0±1.21 0.672
Treg (%) 4.78±1.08 11.50±4.71 <0.001
Breg (%) 7.22±6.38 10.88±7.25 0.123
Memory B (%) 24.86±23.95 25.20±17.85 0.215
Mature B (%) 59.72±25.04 53.93±16.81 0.701
IFN-a (pg/mL) 0.49±1.81 0.40±0.91 0.870
IL-17 (pg/mL) 53.84±48.20 31.27±32.79 0.106
Variable and 
cut-off values
Diagnosing measures p-value of 
SLE predictionAUC(95% CI) SEN SPE PPV NPV
CD3HLA-DR+ (≥13.5%) 0.798 (0.700–0.890) 49.0% 96.0% 96.0% 46.0% <0.001
CD3 (78.25%) 0.546 (0.414–0.678) 54.5% 64.0% 76.9% 39.0% 0.513
CD4 (44.45%) 0.504 (0.375–0.632) 60.0% 52.0% 73.3% 37.1% 0.959
CD8 (25.2%) 0.575 (0.450–0.700) 56.4% 72.0% 81.6% 42.9% 0.285
CD19 (7.55%) 0.603 (0.478–0.727) 60.0% 64.0% 78.6% 42.1% 0.143
NK (10.8%) 0.409 (0.282–0.537) 45.5% 44.0% 64.1% 26.8% 0.196
Ratio (2.35) 0.442 (0.315–0.569) 30.9% 72.0% 70.8% 32.1% 0.409
Treg (9.35%) 0.651 (0.514–0.753) 49.1% 95.8% 96.4% 45.1% 0.036
Breg (9.65%) 0.515 (0.385–0.645) 45.1% 72.0% 71.9% 36.4% 0.834
Memory B (34.2%) 0.285 (0.173–0.398) 26.9% 72.0% 67.9% 33.3% 0.002
Nature B (63.3%) 0.587 (0.461–0.713) 41.2% 96.0% 95.5% 44.4% 0.220
I IFN–a (0.34 pg/mL) 0.517 (0.382–0.653) 7.3% 96.0% 80.0% 32.0% 0.807
I IL–17 (33.95 pg/mL) 0.616 (0.494–0.738) 58.2% 76.0% 84.2% 45.2% 0.098
*AUC–Area under the curve; CI–Confidence Interval; SLE–Systemic Lupus Erythematosus; SEN–sensitivity; SPE–specificity; PPV–
positive predictive value; NPV–negative predictive; p–probability
Figure 1 Receiver operating characteristic (ROC) curve of
potential biomarkers for differentiation between SLE group
and healthy controls. The smallest cut-off value was the
minimum observed test value minus 1, and the largest cut-
off value was the maximum observed test value plus 1. All
the other cut-off values were the average of two consecu-
tively ordered observed test values. 
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analysis suggested that cut-off for the HLA-DR+ T
cells, Treg cells and memory B cells showed good
specificity and positive predictive values for diagnosis
of SLE (Table V).
Discussion
Although the aetiopathogenesis of SLE is
incompletely understood, altered immune processes
play a significant role, an idea that was supported by
the demonstration of autoantibodies against various
tissues, primarily to the cells nuclear material (1–3).
Scientific contribution of current study is to estimate
the value of specific cellular immunity and the level of
cytokines as markers, on the basis of which it would
be possible to identify patients with SLE in immuno -
pathogenesis of the disease. Progress in understand-
ing the immunity of SLE could improve insight into
the disease mechanism and result in concrete bene-
fits for patients.
For a more accurate diagnosis it is necessary to
screen combination of biomarkers for SLE, such as
lymphocyte population. Because of high specificity,
Treg could potentially refer to real SLE patients. In this
way it would be possible to provide an optimal treat-
ment for patients who have a direct benefit from the
specific anti-cytokine therapies. We figured out that
SLE subjects had higher average value (M=9.79%) of
Treg cells compared to control group (M=7.35%)
(p=0.024). But when we examined patients with
active SLE, the percent of Treg was lower compared
to non-active disease (4.78±1.08; 11.50±4.71;
p<0.001). This value was also statistically lower com-
pared to control group (p<0.001). The values of
Breg cells did not demonstrate statistically significant
difference between the SLE and control group.
According to the results ROC curve analysis showed
that Treg could represent good predictor for the clas-
sification of patients with SLE, while Breg cells is not
a good classifier. The cut-off value of Treg was 9.35%,
according to this criterion the sensitivity was 49,1 %
and specificity 95.8%. In relation to these results, we
believe that the value of Treg could be a significant
marker for the patients with (non-active) SLE evalua-
tion, since this cut-off proved to be extremely specific.
However, some authors described different results
regarding Treg cells. Crispin (17) examined 30
untreated patients of whom 10 had active disease, 10
inactive, and 10 were healthy volunteers. Treg cells
were significantly reduced in patients with active dis-
ease compared to controls and patients with inactive
disease (p<0.001), showing the same results for
active SLE from our study. Previous studies have also
examined CD4+CD25hi regulatory T cell frequency
and function in patients with SLE with mixed results.
Suppressive Treg cells are only those with the highest
CD25 expression levels (CD25hi), with the majority of
Treg cells non-suppressive (18). The results have
been mixed in SLE, with different studies finding a
reduced proportion. Possible results diversity can be
explained due to remission (non-active) phase of SLE
patients in our study, so the values  of Treg were high-
er. Yates et al. (19) investigated 21 patients with SLE
and 6 with inactive disease. They found no reduction
in the CD25hi subset, although active disease was
associated with an increased proportion of Treg cells,
but with significant difference when comparing con-
trols and patients with non-active lupus. This indicates
and confirms that the apparent increase in Treg cells
in patients with active disease is accounted by an
increase in the proportion of CD25int cells. Although
there was no apparent increase in the proportion of
CD4+CD25hi T cells, despite an increase in total
Treg cells in patients with active disease, it remained
possible that in lupus patients, in vivo activation may
have resulted in enhanced expression of CD25 in the
CD25int cells. It is possible that in patients with acute
onset of disease, CD4+CD25hi T cells may be
reduced, that is why active lupus is associated with an
increase in total Treg cells by increase of CD25int
cells (19).
In part, the reason for discrepancy between
studies could also be technical difficulties in the phe-
notypic characterization of Treg cells by flow cytome-
try, or characterizing patients with SLE. Crispin (17)
included only small number of patients with active
SLE, while we included 14 patients with active and 41
patients with non-active SLE. Moreover, Suarez (20)
went even further and characterize and quantify cell
populations Treg as CD4+CD25low and CD25high
in controls and patients with SLE. Quantitatively mea-
sured percentage of CD25high cells in 110 SLE
patients was significantly higher compared to the con-
trols, what correlates with our results. Accordingly,
our analysis of Treg cells was well placed and had no
bias to the results. Yan et al. (21) found that the num-
ber of CD4+CD25highFoxP3 cells in inactive SLE
patients is actually higher than in normal controls,
and in the active SLE CD4+CD25high cells show
impaired suppressive function. Venigalla et al. (22)
reported that the number of CD4+CD25highFoxP3
cells in active SLE is higher than in inactive SLE.
However, Valencia et al. (23) in addition to reduced
number of CD4+CD25high Treg in the peripheral
blood of patients with active SLE, demonstrated that
CD4+CD25high for active SLE reduce levels of
FoxP3, and were weaker suppressors of cytokine
secretion and proliferation of effector T cells in vitro.
As T cells also B cells are hyperactive in SLE.
They produce variety of autoantibodies, which result
in the formation of immune complexes, and play a
key role in the effector phase of the disease. In addi-
tion, it also became clear that in SLE T cells are
involved in the attack on target cells and tissues
through the overproduction of proinflammatory
cytokines and increasing adhesion cell-to-cell, which
ultimately leads to apoptosis of target cells (23). One
possibility to explain the phenomenon of autoimmu-
nity diseases such as SLE may refer to lower Treg
function. The lack of function in Treg may result in
increased activity of Th cells or directly in the
increased activity of B cells, which are both regulated
by the Treg in healthy people (17). There are evi-
dences of significance for IL-17, produced by the var-
ious T cells, in SLE. Yang et al. (24) demonstrated
connection with T cells, which produce IL-17 (Th17
cells), and clinical features of the disease activity
score (SLEDAI). Serum IL-17 and the number of
Th17 cells were significantly increased in SLE patients
compared to controls. Elevated levels of IL-17 fre-
quently significantly correlated with SLEDAI (25). The
pathogenesis of SLE is not well understood but it is
known that IL-17 and Th17 cells play an important
role. IL-17A, a family member of IL-17 enhances the
immune response by inducing local production of
cytokines, recruiting neutrophils and monocytes,
increasing antibody production and exacerbates
inflammation and organ damage in SLE (26). In our
study, we found statistically significant difference
(p=0.036) in the levels of serum IL-17 between
patients with SLE (IL-17=49.27 pg/mL) and controls
(IL-17=28.64 pg/ml), and the levels were much
higher in patients with active SLE compared to non-
active, but serum levels of IL-17 did not show signifi-
cant accuracy in diagnosing SLE (AUC=0.696;
p=0.098). While the levels of IL-17 were significantly
higher in patients with SLE, correlation between IFN-
a and IL-17 was not found, as expected. IFN-a, as a
cytokine with pleiotropic effects, may generate an
anti-inflammatory environment or inhibit specific
inflammatory T cells such as Th1 and Th17 cells.
However, it is not known whether IFN-a inhibits the
pro-inflammatory T cells or induce anti-inflammatory
properties in T cells. IFN-a does not inhibit IL-17 in
SLE patients, because it promotes regulatory Th1
response through the secretion of IL-10 (27). In vitro
stimulated CD3+ cells from active SLE patients have
significantly higher levels of IL-17 compared to
healthy controls. Exceptional only T cells isolated
from patients with active disease produce higher lev-
els of IL-17. These results are consistent with previous
research by Yang et al. in which they tested 50
patients (24). Furthermore, Wong and colleagues
(25) have also shown increased concentration of
serum IL-17 in SLE patients compared to healthy con-
trols. Lee et al. (26) proved that the values of IFN-a
were statistically higher in the group of SLE patients
than in the control group. Similar was obtained in our
report, but the difference was not statistically signifi-
cant, and prediction values, despite excellent speci-
ficity, did not show significance for SLE (Table IV). As
observed in our study also Dolff et al. (27) discovered
that patients with active disease had significantly ele-
vated levels of IL-17 expressing T-cells in comparison
to healthy controls (1.46±0.58% vs. 0.93±0.30%,
p=0.007), and active patients had also increased
levels of IL17+ T-cells as compared to inactive
patients (1.46±0.58% vs. 0.88±0.5%, p=0.002).
The results suggest that IL-17 producing cells play a
pivotal role in the pathogenesis of SLE. Dolff et al.
performed in vitro stimulation of CD3+ cells from
active SLE patients which only produced significantly
higher levels of IL-17 compared to healthy controls.
These findings are in accordance with a large previ-
ous study by Yang et al. (24) in which 50 patients
were enrolled. In addition, Wong et al. (25) demon-
strated increased circulating plasma concentrations of
IL-17 in SLE patients as compared to healthy con-
trols.
Flow cytometry might provide useful insights
into the immune status and distribution of lymphocyte
subpopulations. Our study also highlighted the impor-
tance of B cells in the immunopathogenesis of SLE,
demonstrating that CD19+ (B lymphocytes) were sig-
nificantly higher in the SLE group than in control
group (p<0.043), but could not predict SLE
(p=0.143). SLE was traditionally classified as a »B-
cell disease« (28). Subgroups of B lymphocytes play a
key role and have strong association with the disease.
Particularly abnormal activation of human B cells is
associated with the phenotypic markers that correlate
with disease activity. For example, increased peripher-
al CD27-IgD-CD19+ memory B cells in SLE patients
were associated with SLE disease activity, renal dis-
ease and autoantibodies (29). Also, for the number of
peripheral CD19+CD27high B cells a positive corre-
lation with serological abnormalities in SLE patients
was found (16). To understand whether Treg inhibit
these subgroups of B cells in patients with SLE, the
Treg were cultivated with autologous CD19+CD27-
IgD-B cells or autologous CD19+CD27high B cells.
Authors found that Treg induced apoptosis of both B
cells subgroups, and Treg inhibited both subgroups
after B cells stimulation. Treg lymphocytes reduce B
cells, including those, which are associated with
active disease and the production of autoantibodies.
Quantitative deficit of Treg may be primarily responsi-
ble for the impossibility of reducing the B cells. In
other words, less functional Treg attempt to counter-
act with the development of autoimmunity with B
cells in SLE, but they were overwhelmed with unbal-
anced immune homeostasis, which is being devel-
oped together with the progression of disease (29).
Our results showed that group of patients with SLE
had a higher percentage of B lymphocytes (10.43%)
compared to controls (8.15%) (p=0.043), while the
levels were lower in active form of SLE (9.92%), so we
can assume, that in the SLE group, patients had inac-
tive form of disease (12.07% of CD19+ cells), which
was largely unaffected by the Treg, and consequently
no decrease in B cells was observed.
We found that the percentage of activated T
lymphocytes (CD3HLA-DR+) in the patient group
was higher than in the control group (p<0.0005). A
number of studies have demonstrated that T cells iso-
lated from patients with SLE are abnormal, with
regard to their phenotypes and functions compared
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to healthy subjects (30, 31). Other studies in this area
have compared activated T cells in the peripheral
blood of SLE patients with healthy controls. Viallard et
al. (32) found that activated subpopulation of T lym-
phocytes (cytotoxic T lymphocytes CD8+HLA-DR+)
was increased in SLE patients compared to healthy
controls, as was also observed in our analysis. 
The phenotype of T cells isolated from patients
with SLE is abnormal: SLE T cells partially resemble
activated cells and partially behave like anergic (unre-
sponsive) cells. Their response to stimulation through
the T-cell receptor (TCR) is exaggerated, and their
gene expression profile is altered in comparison with
cells obtained from healthy individuals (33). We also
analysed sensitivity and specificity of CD3HLA-DR+
for the detection of SLE using ROC curves and defined
the optimal cut-off for activated T lymphocytes, which
statistically distinguished between patients and healthy
individuals. The optimal cut-off was set at 13.5% of
CD3HLA-DR+ of total T lymphocytes. CD3HLA-DR+
may differentiate SLE patients from healthy controls,
with specificity of 96% and sensitivity of 46%. Despite
low sensitivity the CD3HLA-DR+ lymphocytes could
represent potential biomarker for the diagnosis of SLE,
due to excellent specificity and negative predictive
value (NPV=96%) we could evaluate an algorithm
that would exclude patients with SLE from further eval-
uation and lower the time and cost of diagnostics.
Different data indicate that in the complex pathogen-
esis of SLE activated T cells have an important role
(34). Despite this, there is a lack of reliable biomarkers
for the diagnosis of SLE, monitoring and prediction of
response to the therapy. The existing SLE biomarkers
are often used to diagnose or monitor disease activity,
but the challenge is to discover biomarkers that will be
able to predict the beginning of SLE in susceptible
individuals and predict disease worsening (develop-
ment of flares). New generation of SLE biomarkers
should provide monitoring of the treatment and eval-
uate the success of therapy (15).
The reason for the divergent results in terms of
the number of immune cells could be sought in the
context of several elements. In fact, there are differ-
ences in the phenotypic characterization of immune
cells with flow cytometry, the method of quantifying
cells by flow cytometry and more accurate definition
of SLE disease as active or inactive. We believe, if we
had a larger cohort of patients with SLE, we would be
able to find better statistical differences between the
parameters. Therefore, it is necessary to develop larg-
er studies, also be focused on the multicentre analy-
ses, to assemble more patients that would have given
wider image, because the results in the literature are
divergent. Potential algorithm for SLE patients could
be determined with elevated levels of HLA-
DR+CD3+ (active T-cells), CD19+ B-cells and drop
in relative values of memory B-cell. Differentiation of
patients with active disease, according to our results,
can solely be established with levels of low Treg and
high Th17 cells.
Conclusions
Our results suggested that significant increase in
the relative number of activated T cells, Treg lympho-
cytes, and decrease in memory B cells, as well as
increase level of IL-17 in SLE patients compared to
healthy controls may be implicated in the pathogenesis
of the disease. These parameters, as biomarkers, could
distinguish patients with no SLE and SLE patients.
Moreover, stratification of patients according to the dis-
easestage could also be determined with the relative
value of Treg and Th17 lymphocytes. Mo ni toring sub-
populations of immune cells in peripheral blood using
flow cytometry provides insight into abnormal T and B
cell function in SLE. Further investigations are required
to explain the role and clinical significance of lympho-
cytes in the pathogenesis of SLE. Progress in under-
standing the immunity at SLE, results in concrete ben-
efits for the SLE patients, which include new clinical
management and therapeutic strategies. 
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